Media Coverage

Wednesday, September 7, 2016

CardioCell LLC Retains Objective Capital Partners


San Diego biotech CardioCell LLC has retained Objective Capital Partners, an investment bank and mergers and acquisitions advisory firm, to help the company “manage growth,” the company said in a statement. CardioCell, founded in 2013, is currently planning a late-stage, phase 3 clinical trial for its lead program, and is primed for an “accelerated growth cycle.” READ FULL ARTICLE

Friday, September 2, 2016

ESC: IV Stem Cells for Heart Failure: ‘A Lot More to Learn’


Intravenous infusion of mesenchymal stem cells failed to improve cardiac function in heart failure patients but the treatment did appear to give patients some benefits such as improvement in physical tests, researchers said here. … In a Hot Line presentation here, Butler said that patients did show improvements in secondary endpoints – including the 6-minute walk test, in which those patients who received the stem cells had a 36-meter increase compared with placebo (P=0.02). READ FULL ARTICLE

Tuesday, August 30, 2016

CardioCell reports Phase IIa heart failure data


Data presented at the European Society of Cardiology meeting in Rome showed that a single intravenous administration of ischemic-tolerant mesenchymal stem cells (itMSCs) from CardioCell LLC met the primary safety endpoint and several secondary efficacy endpoints in a single-blind Phase IIa trial to treat chronic heart failure (CHF) in patients with non-ischemic cardiomyopathy. READ FULL ARTICLE

CardioCell announces positive results from phase IIa study evaluating IV administration of stem cells for chronic HF indications


CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announced data from its phase IIa clinical trial “Safety and Efficacy of Intravenous Infusion of Ischemia-Tolerant Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Cardiomyopathy” at the European Society of Cardiology (ESC) Congress. READ FULL ARTICLE

Monday, August 29, 2016

CardioCell stem cells ‘improve well-being’ of heart failure patients


After Celyad failed to reach its primary endpoints in a stem cell therapy test in heart patients back in June, CardioCell has felt the pressure to deliver–and over the weekend posted broadly positive data, but questions, and the need for more clinical data, remain.

The San Diego, CA-based biotech has published new, top-line data from the ESC Congress in Rome, Italy that used its allogeneic mesenchymal stem cells, delivered through an IV, to heart failure patients with non-ischemic cardiomyopathy. READ FULL ARTICLE

Older Entries »